BRAF and non-small cell lung carcinoma: In April 2018, the test was approved in Japan as a companion diagnostic for the identification of NSCLC patients who might benefit from therapies that target the V600E mutation of BRAF. In December 2018, it was granted reimbursement coverage for the BRAF mutation indication as a companion diagnostic for dabrafenib in combination with trametinib.